World Tumor Marker Testing Market Review by VPG Now Available at

LONDON--(BUSINESS WIRE)-- Today, there are only a handful of well-established tumor markers that are routinely used by physicians. Many other potential markers are still being researched. Some markers cause great excitement when they are first discovered but, upon further investigation, prove to be no more useful than markers already in use.

The goal is to be able to screen for and diagnose cancer early, when it is the most treatable and before it has had a chance to grow and spread. So far, the only tumor marker to gain wide acceptance as a screening test is Prostate Specific Antigen (PSA) for prostate cancer in men. Even with PSA there is continued debate among experts and national organizations over the usefulness of this test for screening asymptomatic men. Other markers are either not specific enough or they are not elevated early enough in the disease process to be useful for screening.

New research report “Analysis of Tumor Marker Testing Instrumentation And Strategic Profiles of Leading Suppliers” elaborated by Venture Planning Group (VPG) reviews current instrumentation technologies, and compares features of major automated and semiautomated analyzers used for tumor marker testing.

Furthermore, strategic assessments of current and emerging suppliers of tumor marker diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies, are also provided.

Report Details:

Title: Analysis of Tumor Marker Testing Instrumentation And Strategic Profiles of Leading Suppliers

Published: September, 2012

Pages: 119

Price: US$ 3,500.00

More Healthcare Equipment & Services Market Research Reports by VPG Include:

More new market research reports by VPG can be found at

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970

Source: The Market Publishers, Ltd.